Biophytis Strengthens Financial Position with Cash Runway into 2027

Biophytis has solidified its financial foundation, extending its cash runway into Q1 2027. The company's recent financial activities include a strengthened cash position of €3.0 million, primarily from the exercise of 2026 share warrants which amounted to €2.5 million. Additionally, drawdowns from the Hexagon bond facility contributed €1.2 million. Operating cash outflows were limited to €0.7 million.

Biophytis also reduced its financial debt by over 30% through debt-to-equity conversions, dropping from €4.3 million in December 2025 to €2.9 million by the end of August 2026. This restructuring allows better financial visibility as the company prepares to initiate its Phase 2 obesity study in early 2027 and advances its Hong Kong JV for a Phase 3 study in sarcopenia.